Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of VirtualScopics Inc (NASDAQ: VSCP) acted responsibly on behalf of investors’ profitability in the planned sale to BioTelemetry Inc (NASDAQ: BEAT).

On March 25, 2016, VirtualScopics Inc (NASDAQ: VSCP) and BioTelemetry Inc (NASDAQ: BEAT) announced that they had entered into a merger agreement. Under the terms of the agreement, VirtualScopics common shareholders will receive $4.05 per share, Series A and Series B Convertible Preferred Stock shareholders will receive $336.30 per share and Series C-1 Convertible Preferred Stock holders will receive $920.00 per share.

Based in Rochester, New York, and founded in 2000 VirtualScopics Inc provides imaging solutions to the pharmaceutical, biotechnology, and medical device industries.

The investigation focuses on whether NASDAQ: VSCP investors received the highest price and whether the directors of VirtualScopics Inc acted in the best interest of VirtualScopics Inc company and its shareholders.   

If you purchased VirtualScopics Inc (NASDAQ: VSCP) prior to March 25, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185